Molecular Pathology of Cancer

癌症的分子病理学

• 批准号: 9126427
• 负责人: Boris C. Bastian
• 金额: $ 25.73万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-12 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9126427
• 关键词: Malignant Neoplasms; molecular pathology

DESCRIPTION (provided by applicant): This application is for a new institutional Ruth L. Kirschstein National Research Service Award (NRSA) T32 training grant to support the research training of six postdoctoral fellows in the Molecular Pathology of Cancer at the University of California, San Francisco (UCSF). The objective of this Program is to equip the most promising young cancer researchers recruited to our institution with the skills necessary both to advance scientific knowledge into human malignancy and effectively translate laboratory-based oncology discoveries into the clinic. Recent advances in molecular oncology and cancer genomics have created an unprecedented opportunity to study malignancy in cancer patients and their tissues, and use this information to develop mechanism-based diagnostic and therapeutic strategies to revolutionize patient care. The underlying rationale for this Program is that the development of personalized cancer therapy must be driven by the molecular pathology of the tumor. To keep pace with accelerating discoveries in cancer biology and catalyze clinical translation, we need to increase the number of highly trained translational physicians and scientists with an appreciation of the pathologic as well as genetic aberrations of cancer. This is the first training grant on this theme at UCSF and one of the few nationwide that brings together investigators focused on fundamental research in cancer biology, the molecular diagnosis of cancer, and personalized targeted therapy for cancer patients. Administration and scientific direction of the Program will be through the UCSF Departments of Pathology and Laboratory Medicine, providing an ideal setting where cutting edge cell and molecular biology expertise can be leveraged against our large tumor banks and combined with the newest technologies in cancer diagnostics. The 34 outstanding faculty members in the program are a mix of basic cancer biologists and physician-scientists with diverse clinical and scientific training in oncologic diseases. T32 trainees will receive highly personalized, multidisciplinary training that includes the following five key elements: (1) An intense research experience in which each trainee is co-mentored by a basic investigator and a clinical/translational scientist; (2) Hands-on exposure to a broad range of cancer-relevant analyses, including mutation panel testing and whole genome sequencing, bioinformatic approaches in a research setting and CLIA-licensed clinical laboratories; (3) Formal coursework in cancer biology, cancer pathology, translational oncology, and clinical trial development; (4) Weekly seminar series given by distinguished cancer researchers from outside academic institutions and bio/pharmaceutical companies in the Bay area and beyond; (5) Ongoing performance evaluation and formal career development workshops. We provide evidence that UCSF has the vision, expertise, and infrastructure to train the next generation of leaders in translational cancer research.

描述（由申请人提供）：本申请适用于新机构 Ruth L. Kirschstein 国家研究服务奖 (NRSA) T32 培训补助金，用于支持加州大学圣路易斯分校癌症分子病理学领域的六名博士后研究员的研究培训弗朗西斯科（加州大学旧金山分校）。该计划的目标是为我们机构招募的最有前途的年轻癌症研究人员提供必要的技能，以推进人类恶性肿瘤的科学知识，并有效地将基于实验室的肿瘤学发现转化为临床。分子肿瘤学和癌症基因组学的最新进展为研究癌症患者及其组织的恶性肿瘤创造了前所未有的机会，并利用这些信息开发基于机制的诊断和治疗策略，以彻底改变患者护理。该计划的基本原理是个性化癌症治疗的发展必须由肿瘤的分子病理学驱动。为了跟上癌症生物学不断加速的发现并促进临床转化，我们需要增加训练有素的转化医生和科学家的数量，他们了解癌症的病理和遗传畸变。这是第一次训练 加州大学旧金山分校针对这一主题提供了资助，也是全国为数不多的几个聚集了专注于癌症生物学基础研究、癌症分子诊断和癌症患者个性化靶向治疗的研究人员的机构之一。该计划的管理和科学指导将通过加州大学旧金山分校病理学和实验医学系进行，提供一个理想的环境，可以利用我们大型肿瘤库的尖端细胞和分子生物学专业知识，并与癌症诊断的最新技术相结合。该项目的 34 名杰出教职人员包括基础癌症生物学家和医学科学家，他们在肿瘤疾病方面接受过多种临床和科学培训。 T32学员将接受高度个性化、多学科的培训，其中包括以下五个关键要素：（1）深入的研究经验，每位学员都由一名基础研究者和一名临床/转化科学家共同指导； (2) 亲身接触广泛的癌症相关分析，包括突变面板测试和全基因组测序、研究环境中的生物信息学方法和 CLIA 许可的临床实验室； (3) 癌症生物学、癌症病理学、转化肿瘤学和临床试验开发的正式课程； (4) 每周由来自湾区及其他地区学术机构和生物/制药公司的杰出癌症研究人员举办的系列研讨会； (5) 持续的绩效评估和正式的职业发展研讨会。我们提供的证据表明加州大学旧金山分校拥有培养下一代转化癌症研究领导者的愿景、专业知识和基础设施。